A Mab A Case Study In Bioprocess Development

The production process included a dedicated after elution.

The is a landmark industry document developed by the CMC Biotech Working Group to demonstrate the practical application of Quality by Design (QbD) principles to the development and manufacturing of monoclonal antibodies (mAbs) . Unlike traditional "test-to-quality" approaches, this study illustrates how to "build quality into" a product through deep process understanding and risk management. 1. Core Concept: Quality by Design (QbD) A Mab A Case Study In Bioprocess Development

Regulatory guidance for process validation is provided by bodies like the FDA and EMA, with key frameworks coming from the . ICH guidelines such as Q8 (Quality by Design), Q9 (Risk Management), Q10 (Pharmaceutical Quality System), and Q11 (Drug Substance Development) are foundational. The FDA's guidance on PV outlines a three-stage approach: Stage 1 (Process Design), Stage 2 (Process Qualification), and Stage 3 (Continued Process Verification). For Process Performance Qualification (PPQ) , agencies typically require data from three consecutive commercial-scale batches to demonstrate consistent performance. The production process included a dedicated after elution